Increased NLRP3 inflammasome expression in peripheral blood mononuclear cells of patients with schizophrenia: a case-control study

References

• Al-Dujaili, A. H., Mousa, R. F., Al-Hakeim, H. K., & Maes, M. (2021). High mobility group protein 1 and Dickkopf-related protein 1 in schizophrenia and treatment-resistant schizophrenia: Associations with interleukin-6, symptom domains, and neurocognitive impairments. Schizophrenia Bulletin, 47(2), 530–541. https://doi.org/10.1093/schbul/sbaa136
   PubMed Web of Science ®Google Scholar
• Andreasen, N. C. (1990). Methods for assessing positive and negative symptoms. Modern Problems of Pharmacopsychiatry, 24, 73–88. https://doi.org/10.1159/000418013
   PubMedGoogle Scholar
• Aydemir, O., & Uykur, B. (2012). Reliability and validity study of the Turkish version of functioning assessment short test in bipolar disorder. Turkish Journal of Psychiatry, 23(3), 193–200.
   Google Scholar
• Bauer, M. E., & Teixeira, A. L. (2019). Inflammation in psychiatric disorders: What comes first? Annals of the New York Academy of Sciences, 1437(1), 57–67. https://doi.org/10.1111/nyas.13712
   PubMed Web of Science ®Google Scholar
• Calovi, S., Mut-Arbona, P., Tod, P., Iring, A., Nicke, A., Mato, S., Vizi, E. S., Tonnesen, J., & Sperlagh, B. (2020). P2X7 receptor-dependent layer-specific changes in neuron-microglia reactivity in the prefrontal cortex of a phencyclidine induced mouse model of schizophrenia. Frontiers in Molecular Neuroscience, 13, 566251. https://doi.org/10.3389/fnmol.2020.566251
   PubMed Web of Science ®Google Scholar
• Charlson, F. J., Ferrari, A. J., Santomauro, D. F., Diminic, S., Stockings, E., Scott, J. G., McGrath, J. J., & Whiteford, H. A. (2018). Global epidemiology and burden of schizophrenia: Findings from the Global Burden of Disease Study 2016. Schizophrenia Bulletin, 44(6), 1195–1203. https://doi.org/10.1093/schbul/sby058
   PubMed Web of Science ®Google Scholar
• Cullen, A. E., Holmes, S., Pollak, T. A., Blackman, G., Joyce, D. W., Kempton, M. J., Murray, R. M., McGuire, P., & Mondelli, V. (2019). Associations between non-neurological autoimmune disorders and psychosis: A meta-analysis. Biological Psychiatry, 85(1), 35–48. https://doi.org/10.1016/j.biopsych.2018.06.016
   PubMed Web of Science ®Google Scholar
• Dinesh, A. A., Islam, J., Khan, J., Turkheimer, F., & Vernon, A. C. (2020). Effects of antipsychotic drugs: Cross talk between the nervous and innate immune system. CNS Drugs, 34(12), 1229–1251. https://doi.org/10.1007/s40263-020-00765-x
   PubMed Web of Science ®Google Scholar
• Erkoç, Ş., Arkonaç, O., Ataklı, C., & Özmen, E. (1991a). Negatif semptomları değerlendirme ölçeğinin güvenilirliği ve geçerliliği. Düşünen Adam, 4, 16–19.
   Google Scholar
• Erkoç, Ş., Arkonaç, O., Ataklı, C., & Özmen, E. (1991b). Pozitif semptomları değerlendirme ölçeğinin güvenilirliği ve geçerliliği. Düşünen Adam, 4, 20–24.
   Google Scholar
• Fond, G., Faugere, M., Richieri, R., Cermolacce, M., Korchia, T., Micoulaud-Franchi, J. A., Sunhary de Verville, P. L., Boyer, L., & Lancon, C. (2021). Depressive symptoms and chronic peripheral inflammation are associated with impaired functional remission in schizophrenia independently of psychotic remission. Journal of Affective Disorders, 280(Pt A), 267–271. https://doi.org/10.1016/j.jad.2020.11.046
   PubMedGoogle Scholar
• Fraguas, D., Diaz-Caneja, C. M., Ayora, M., Hernandez-Alvarez, F., Rodriguez-Quiroga, A., Recio, S., Leza, J. C., & Arango, C. (2019). Oxidative stress and inflammation in first-episode psychosis: A systematic review and meta-analysis. Schizophrenia Bulletin, 45(4), 742–751. https://doi.org/10.1093/schbul/sby125
   PubMed Web of Science ®Google Scholar
• Fries, G. R., Dimitrov, D. H., Lee, S., Braida, N., Yantis, J., Honaker, C., Cuellar, J., & Walss-Bass, C. (2018). Genome-wide expression in veterans with schizophrenia further validates the immune hypothesis for schizophrenia. Schizophrenia Research, 192, 255–261. https://doi.org/10.1016/j.schres.2017.06.016
   PubMed Web of Science ®Google Scholar
• Ganguli, R., Yang, Z., Shurin, G., Chengappa, K. N., Brar, J. S., Gubbi, A. V., & Rabin, B. S. (1994). Serum interleukin-6 concentration in schizophrenia: Elevation associated with duration of illness. Psychiatry Research, 51(1), 1–10. https://doi.org/10.1016/0165-1781(94)90042-6
   PubMed Web of Science ®Google Scholar
• Giridharan, V. V., Scaini, G., Colpo, G. D., Doifode, T., Pinjari, O. F., Teixeira, A. L., Petronilho, F., Macedo, D., Quevedo, J., & Barichello, T. (2020). Clozapine prevents poly (I:C) induced inflammation by modulating NLRP3 pathway in microglial cells. Cells, 9(3), 577. https://doi.org/10.3390/cells9030577
   PubMed Web of Science ®Google Scholar
• Gubert, C., Fries, G. R., Pfaffenseller, B., Ferrari, P., Coutinho-Silva, R., Morrone, F. B., Kapczinski, F., & Battastini, A. M. O. (2016). Role of P2X7 receptor in an animal model of mania induced by D-amphetamine. Molecular Neurobiology, 53(1), 611–620. https://doi.org/10.1007/s12035-014-9031-z
   PubMed Web of Science ®Google Scholar
• He, Y., Hara, H., & Núñez, G. (2016). Mechanism and regulation of NLRP3 inflammasome activation. Trends in Biochemical Sciences, 41(12), 1012–1021. https://doi.org/10.1016/j.tibs.2016.09.002
   PubMed Web of Science ®Google Scholar
• Hong, S., Lee, E. E., Martin, A. S., Soontornniyomkij, B., Soontornniyomkij, V., Achim, C. L., Reuter, C., Irwin, M. R., Eyler, L. T., & Jeste, D. V. (2017). Abnormalities in chemokine levels in schizophrenia and their clinical correlates. Schizophrenia Research, 181, 63–69. https://doi.org/10.1016/j.schres.2016.09.019
   PubMed Web of Science ®Google Scholar
• Janks, L., Sharma, C. V. R., & Egan, T. M. (2018). A central role for P2X7 receptors in human microglia. Journal of Neuroinflammation, 15(1), 325. https://doi.org/10.1186/s12974-018-1353-8
   PubMedGoogle Scholar
• Jeppesen, R., & Benros, M. E. (2019). Autoimmune diseases and psychotic disorders. Frontiers in Psychiatry, 10, 131. https://doi.org/10.3389/fpsyt.2019.00131
   PubMed Web of Science ®Google Scholar
• Jeppesen, R., Christensen, R. H. B., Pedersen, E. M. J., Nordentoft, M., Hjorthoj, C., Kohler-Forsberg, O., & Benros, M. E. (2020). Efficacy and safety of anti-inflammatory agents in treatment of psychotic disorders - A comprehensive systematic review and meta-analysis. Brain Behavior and Immunity, 90, 364–380. https://doi.org/10.1016/j.bbi.2020.08.028
   PubMed Web of Science ®Google Scholar
• Jia, P., Wang, L., Meltzer, H. Y., & Zhao, Z. (2010). Common variants conferring risk of schizophrenia: a pathway analysis of GWAS data. Schizophrenia Research, 122(1–3), 38–42. https://doi.org/10.1016/j.schres.2010.07.001
   PubMed Web of Science ®Google Scholar
• Kim, H. K., Andreazza, A. C., Elmi, N., Chen, W., & Young, L. T. (2016). Nod-like receptor pyrin containing 3 (NLRP3) in the post-mortem frontal cortex from patients with bipolar disorder: A potential mediator between mitochondria and immune-activation. Journal of Psychiatric Research, 72, 43–50. https://doi.org/10.1016/j.jpsychires.2015.10.015
   PubMed Web of Science ®Google Scholar
• Kogan, S., Ospina, L. H., & Kimhy, D. (2018). Inflammation in individuals with schizophrenia - Implications for neurocognition and daily function. Brain, Behavior, and Immunity, 74, 296–299. https://doi.org/10.1016/j.bbi.2018.09.016
   PubMed Web of Science ®Google Scholar
• Kovanyi, B., Csolle, C., Calovi, S., Hanuska, A., Kato, E., Koles, L., Bhattacharya, A., Haller, J., & Sperlagh, B. (2016). The role of P2X7 receptors in a rodent PCP-induced schizophrenia model. Scientific Reports, 6, 36680. https://doi.org/10.1038/srep36680
   PubMed Web of Science ®Google Scholar
• Liu, R., Tang, W., Wang, W., Xu, F., Fan, W., Zhang, Y., & Zhang, C. (2021). NLRP3 influences cognitive function in schizophrenia in Han Chinese. Frontiers in Genetics, 12, 781625. https://doi.org/10.3389/fgene.2021.781625
   PubMed Web of Science ®Google Scholar
• Lord, B., Aluisio, L., Shoblock, J. R., Neff, R. A., Varlinskaya, E. I., Ceusters, M., Lovenberg, T. W., Carruthers, N., Bonaventure, P., Letavic, M. A., Deak, T., Drinkenburg, W., & Bhattacharya, A. (2014). Pharmacology of a novel central nervous system-penetrant P2X7 antagonist JNJ-42253432. The Journal of Pharmacology and Experimental Therapeutics, 351(3), 628–641. https://doi.org/10.1124/jpet.114.218487
   PubMed Web of Science ®Google Scholar
• Luo, Y., He, H., Zhang, J., Ou, Y., & Fan, N. (2019). Changes in serum TNF-alpha, IL-18, and IL-6 concentrations in patients with chronic schizophrenia at admission and at discharge. Comprehensive Psychiatry, 90, 82–87. https://doi.org/10.1016/j.comppsych.2019.01.003
   PubMed Web of Science ®Google Scholar
• McCutcheon, R. A., Reis Marques, T., & Howes, O. D. (2020). Schizophrenia-An overview. JAMA Psychiatry, 77(2), 201–210. https://doi.org/10.1001/jamapsychiatry.2019.3360
   PubMed Web of Science ®Google Scholar
• McGrath, J., Saha, S., Chant, D., & Welham, J. (2008). Schizophrenia: A concise overview of incidence, prevalence, and mortality. Epidemiologic Reviews, 30, 67–76. https://doi.org/10.1093/epirev/mxn001
   PubMed Web of Science ®Google Scholar
• Muller, N., Weidinger, E., Leitner, B., & Schwarz, M. J. (2015). The role of inflammation in schizophrenia. Frontiers in Neuroscience., 9, 372. https://doi.org/10.3389/fnins.2015.00372
   PubMed Web of Science ®Google Scholar
• Orlovska-Waast, S., Kohler-Forsberg, O., Brix, S. W., Nordentoft, M., Kondziella, D., Krogh, J., & Benros, M. E. (2019). Cerebrospinal fluid markers of inflammation and infections in schizophrenia and affective disorders: A systematic review and meta-analysis. Molecular Psychiatry, 24(6), 869–887. https://doi.org/10.1038/s41380-018-0220-4
   PubMed Web of Science ®Google Scholar
• Pandurangi, A. K., & Buckley, P. F. (2020). Inflammation, antipsychotic drugs, and evidence for effectiveness of anti-inflammatory agents in schizophrenia. Current Topics in Behavioral Neurosciences, 44, 227–244. https://doi.org/10.1007/7854_2019_91
   PubMedGoogle Scholar
• Ripke, S., O'Dushlaine, C., Chambert, K., Moran, J. L., Kähler, A. K., Akterin, S., Bergen, S. E., Collins, A. L., Crowley, J. J., Fromer, M., Kim, Y., Lee, S. H., Magnusson, P. K. E., Sanchez, N., Stahl, E. A., Williams, S., Wray, N. R., Xia, K., Bettella, F., … Sullivan, P. F, Wellcome Trust Case Control Consortium 2 (2013). Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nature Genetics, 45(10), 1150–1159. https://doi.org/10.1038/ng.2742
   PubMed Web of Science ®Google Scholar
• Rodrigues-Amorim, D., Rivera-Baltanas, T., Spuch, C., Caruncho, H. J., Gonzalez-Fernandez, A., Olivares, J. M., & Agis-Balboa, R. C. (2018). Cytokines dysregulation in schizophrenia: A systematic review of psychoneuroimmune relationship. Schizophrenia Research, 197, 19–33. https://doi.org/10.1016/j.schres.2017.11.023
   PubMed Web of Science ®Google Scholar
• Rosa, A. R., Sanchez-Moreno, J., Martinez-Aran, A., Salamero, M., Torrent, C., Reinares, M., Comes, M., Colom, F., Van Riel, W., Ayuso-Mateos, J. L., Kapczinski, F., & Vieta, E. (2007). Validity and reliability of the Functioning Assessment Short Test (FAST) in bipolar disorder. Clinical Practice and Epidemiology in Mental Health, 3(1), 5. https://doi.org/10.1186/1745-0179-3-5
   PubMedGoogle Scholar
• Strassnig, M., Bowie, C., Pinkham, A. E., Penn, D., Twamley, E. W., Patterson, T. L., & Harvey, P. D. (2018). Which levels of cognitive impairments and negative symptoms are related to functional deficits in schizophrenia? Journal of Psychiatric Research, 104, 124–129. https://doi.org/10.1016/j.jpsychires.2018.06.018
   PubMed Web of Science ®Google Scholar
• Syed, A. A. S., He, L., Shi, Y., & Mahmood, S. (2021). Elevated levels of IL-18 associated with schizophrenia and first episode psychosis: A systematic review and meta-analysis. Early Intervention in Psychiatry, 15(4), 896–905. https://doi.org/10.1111/eip.13031
   PubMed Web of Science ®Google Scholar
• Szabo, A., O'Connell, K. S., Ueland, T., Sheikh, M. A., Agartz, I., Andreou, D., Aukrust, P., Boye, B., Boen, E., Drange, O. K., Elvsashagen, T., Engh, J. A., Hope, S., Collier Hoegh, M., Joa, I., Johnsen, E., Kroken, R. A., Vik Lagerberg, T., Lekva, T., … Djurovic, S. (2022). Increased circulating IL-18 levels in severe mental disorders indicate systemic inflammasome activation. Brain, Behavior, and Immunity, 99, 299–306. https://doi.org/10.1016/j.bbi.2021.10.017
   PubMed Web of Science ®Google Scholar
• Talukdar, P. M., Abdul, F., Maes, M., Berk, M., Venkatasubramanian, G., Kutty, B. M., & Debnath, M. (2021). A proof-of-concept study of maternal immune activation mediated induction of Toll-like receptor (TLR) and inflammasome pathways leading to neuroprogressive changes and schizophrenia-like behaviours in offspring. European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology, 52, 48–61. https://doi.org/10.1016/j.euroneuro.2021.06.009
   PubMed Web of Science ®Google Scholar
• Ventura, L., Freiberger, V., Thiesen, V. B., Dias, P., Dutra, M. L., Silva, B. B., Schlindwein, A. D., & Comim, C. M. (2020). Involvement of NLRP3 inflammasome in schizophrenia-like behaviour in young animals after maternal immune activation. Acta Neuropsychiatrica, 32(6), 321–327. https://doi.org/10.1017/neu.2020.27
   PubMed Web of Science ®Google Scholar
• Wedervang-Resell, K., Friis, S., Lonning, V., Smelror, R. E., Johannessen, C., Reponen, E. J., Lyngstad, S. H., Lekva, T., Aukrust, P., Ueland, T., Andreassen, O. A., Agartz, I., & Myhre, A. M. (2020). Increased interleukin 18 activity in adolescents with early-onset psychosis is associated with cortisol and depressive symptoms. Psychoneuroendocrinology, 112, 104513. https://doi.org/10.1016/j.psyneuen.2019.104513
   PubMed Web of Science ®Google Scholar
• Wu, J. Q., Chen, D. C., Tan, Y. L., Tan, S. P., Xiu, M. H., Wang, Z. R., Yang, F. D., Soares, J. C., & Zhang, X. Y. (2016). Altered interleukin-18 levels are associated with cognitive impairment in chronic schizophrenia. Journal of Psychiatric Research, 76, 9–15. https://doi.org/10.1016/j.jpsychires.2016.01.013
   PubMed Web of Science ®Google Scholar
• Xiu, M. H., Chen, D. C., Wang, D., Zhang, K., Dong, A., Tang, W., Zhang, F., Liu, L. J., Liu, J. H., Liu, H. B., Yang, F. D., Kosten, T. R., & Zhang, X. Y. (2012). Elevated interleukin-18 serum levels in chronic schizophrenia: Association with psychopathology. Journal of Psychiatric Research, 46(8), 1093–1098. https://doi.org/10.1016/j.jpsychires.2012.04.026
   PubMed Web of Science ®Google Scholar
• Xu, Y., Yue, W., Shugart, Y. Y., Yuan, J., Wang, G., Wang, H. Z., Lehrman, B., Zhang, F., & Zhang, D. (2016). Potential involvement of the interleukin-18 pathway in schizophrenia. Journal of Psychiatric Research, 74, 10–16. https://doi.org/10.1016/j.jpsychires.2015.12.013
   PubMed Web of Science ®Google Scholar
• Yue, N., Huang, H., Zhu, X., Han, Q., Wang, Y., Li, B., Liu, Q., Wu, G., Zhang, Y., & Yu, J. (2017). Activation of P2X7 receptor and NLRP3 inflammasome assembly in hippocampal glial cells mediates chronic stress-induced depressive-like behaviors. Journal of neuroinflammation, 14(1), 102. https://doi.org/10.1186/s12974-017-0865-y
   PubMedGoogle Scholar
• Zhang, X. Y., Tan, Y. L., Chen, D. C., Tan, S. P., Malouta, M. Z., Bernard, J. D., Combs, J. L., Bhatti, S., Davis, M. C., Kosten, T. R., & Soares, J. C. (2016). Serum IL-18 level, clinical symptoms and IL-18-607A/C polymorphism among chronic patients with schizophrenia in a Chinese Han population. Psychoneuroendocrinology, 68, 140–147. https://doi.org/10.1016/j.psyneuen.2016.03.002
   PubMed Web of Science ®Google Scholar
• Zhang, Y., Liu, L., Peng, Y. L., Liu, Y. Z., Wu, T. Y., Shen, X. L., Zhou, J. R., Sun, D. Y., Huang, A. J., Wang, X., Wang, Y. X., & Jiang, C. L. (2014). Involvement of inflammasome activation in lipopolysaccharide-induced mice depressive-like behaviors. CNS Neuroscience & Therapeutics, 20(2), 119–124. https://doi.org/10.1111/cns.12170
   PubMed Web of Science ®Google Scholar